KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+/HER2- advanced breast cancer: Final results of the randomized phase III MONARCH plus trial.

Chin Med J (Engl) · 2025-Jun-20 · PMID 39385327

Panel B质量警告待 EXE 对齐验证

PFS

Figure 1 Kaplan–Meier plot of PFS in the ITT population in (A) cohort A and (B) cohort B. * HR stratified by nature of disease and prior ET; † Log-rank stratified nominal P value (two-sided) for comparison of treatment vs. placebo + NSAI; ‡ HR stratified by nature of disease, sensitivity to ET; § Log-rank stratified nominal P -value (two-sided) for comparison of treatment vs. placebo + fulvestrant. CI: Confidence interval; ET: Endocrine therapy; HR: Hazard ratio; ITT: Intention-to-treat; NSAI: Non-steroidal aromatase inhibitor; PFS: Progression-free survival.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.79
质量通过否
预期曲线2
实际曲线1
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0quality_warning待验证12026-07-23T18:07:22+00:00